查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602734

貧血治療藥物市場：按藥物、類型、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Anemia Drugs Market by Drug (Alglucerase Injection, Carbonyl Iron, Cyanocobalamin), Type (Aplastic Anemia, Chronic Kidney Disease Anemia, Hemolytic Anemia), Route of Administration, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年貧血治療藥物市場規模為195.5億美元，預計2024年將達212.4億美元，複合年成長率為10.76%，到2030年將達到399.9億美元。

貧血治療市場包括多種旨在解決不同類型貧血的治療解決方案，包括缺鐵性貧血、鐮狀細胞性貧血。這些藥物透過刺激紅血球產生或增加血紅素水平來發揮作用。這種疾病的流行強調了對治療貧血藥物的需求，這種疾病影響著全世界很大一部分人口，特別是婦女、兒童和老年人。這些藥物應用於包括醫院和診所在內的整個醫療機構，已成為慢性腎臟病病患者、孕婦和接受化療的患者治療方法的重要組成部分。此外，也有口服製劑可供選擇，因此市場的最終用途延伸到居家醫療環境。影響市場的主要成長要素包括營養不良引起的貧血（尤其是缺鐵性貧血）的增加、人口趨勢以及人口老化的增加。意識和診斷的提高，加上新興地區醫療基礎設施的擴大，正在進一步推動市場擴張。透過投資開發新藥（包括生物相似藥和生技藥品）並擴展到服務不足的市場來利用最新機會。然而，挑戰仍然存在，包括嚴格的法律規範、高昂的治療成本、潛在的副作用和藥物召回。創新機會在於開發標靶治療和個人化醫療，以及改進的給藥系統，以提高患者的依從性和治療結果。該市場的特點是研發活動頻繁，並專注於策略夥伴關係關係，以促進創新和擴大地域覆蓋範圍。儘管存在巨大的成長潛力，但公司必須策略性地應對和應對監管挑戰和價格敏感性，特別是在新興市場。貧血治療市場的創新時機仍然成熟，基因組學和生物技術在塑造其未來方面發揮關鍵作用。

主要市場統計
基準年[2023] 195.5億美元
預測年份 [2024] 212.4億美元
預測年份 [2030] 399.9億美元
複合年成長率（%） 10.76%

市場動態：揭示快速發展的貧血藥物市場的關鍵市場洞察

供需的動態交互作用正在改變貧血藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病和貧血盛行率增加
    • 生活方式的改變以及包裝和食品食品的過度消費
    • 人口變化和育齡婦女的增加
  • 市場限制因素
    • 與過量攝取貧血治療藥物相關的副作用
  • 市場機會
    • 政府核准開發新的和創新的貧血治療方法
    • 貧血治療藥物的研發活動
  • 市場挑戰
    • 貧血藥物因安全問題被召回

波特的五力：駕馭貧血藥物市場的策略工具

波特的五力架構是了解貧血治療藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對貧血藥物市場的影響

外部宏觀環境因素在塑造貧血治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解貧血治療藥物市場的競爭狀況

貧血治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣貧血治療市場供應商的績效評估

FPNV 定位矩陣是評估貧血治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製貧血治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對貧血治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和貧血的增加
      • 生活方式的改變以及包裝和食品食品的過度消費
      • 人口變化和育齡婦女人數的增加
    • 抑制因素
      • 與過量攝取貧血治療藥物相關的副作用
    • 機會
      • 政府核准開發新的和創新的貧血治療方法
      • 貧血治療藥物生產的研發活動
    • 任務
      • 貧血藥物因安全問題被召回
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 貧血治療藥物（依市場藥品分類）

  • 阿糖酶注射液
  • 羰基鐵
  • 氰鈷胺素
  • Darbepoetin汀阿爾法
  • Eculizumab
  • 依泊汀BETA-甲氧基聚乙二醇
  • 富馬酸亞鐵
  • 聚葡萄糖鐵
  • 鐵補充品

第7章貧血治療藥物市場：依類型

  • 再生障礙性貧血
  • 慢性腎臟病貧血
  • 溶血性貧血
  • 缺鐵性貧血
  • 惡性貧血
  • 鐮狀細胞性貧血
  • 維生素缺乏性貧血

第8章貧血治療藥物市場：依給藥途徑分類

  • 可注射的
  • 口服

第9章貧血治療藥物市場：依最終用戶分類

  • 醫院
  • 自我管理

第10章北美及南美洲貧血治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區貧血治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲貧血治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc. by Allergan PLC
  • ADZO Lifesciences Pvt Ltd.
  • Akebia Therapeutics, Inc.
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Ltd.
  • Aqunova Pharma Private Limited
  • Astraea Life Sciences Pvt Ltd
  • Bluebird Bio, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Corona Remedies Pvt Ltd.
  • Covis Pharma GmbH
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Gujarat Terce Laboratories Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Pharmacosmos A/S
  • Pieris Pharmaceuticals, Inc.
  • Sanofi SA
  • Solitaire Pharmacia Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Triton Healthcare Pvt Ltd.
Product Code: MRR-DD0700E81E02

The Anemia Drugs Market was valued at USD 19.55 billion in 2023, expected to reach USD 21.24 billion in 2024, and is projected to grow at a CAGR of 10.76%, to USD 39.99 billion by 2030.

The anemia drugs market encompasses a wide range of therapeutic solutions designed to address various types of anemia, including iron deficiency anemia, aplastic anemia, and sickle cell anemia. These drugs work by either stimulating red blood cell production or increasing hemoglobin levels. The necessity for anemia drugs is underscored by the condition's prevalence, which affects large segments of the population globally, particularly women, children, and the elderly. Applications span across healthcare institutions, including hospitals and clinics, with these drugs being an integral component of treatment regimens for chronic kidney disease patients, pregnant women, and individuals undergoing chemotherapy. The market's end-use scope also extends to homecare settings due to the available oral formulations. Key growth factors influencing this market include rising incidences of anemia, especially iron deficiency anemia, backed by poor nutrition, demographic trends, and a growing aging population. Increased awareness and diagnosis combined with the expansion of healthcare infrastructure in emerging regions further support market expansion. Latest opportunities can be grasped through investments in novel drug development, including biosimilars and biologics, as well as geographic expansion into underserved markets. However, challenges persist, such as stringent regulatory frameworks, high treatment costs, possible side effects, and drug recalls. Innovation opportunities lie in the development of targeted therapies and personalized medicine, alongside improvements in delivery systems to enhance patient compliance and outcomes. The market is characterized by robust R&D activities and a focus on strategic partnerships to foster innovation and expand reach. While substantial growth potential exists, firms must strategically navigate and address regulatory challenges and price sensitivity, particularly in emerging markets. The anemia drugs market remains ripe for innovation, with genomics and biotechnology playing pivotal roles in shaping its future.

KEY MARKET STATISTICS
Base Year [2023] USD 19.55 billion
Estimated Year [2024] USD 21.24 billion
Forecast Year [2030] USD 39.99 billion
CAGR (%) 10.76%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anemia Drugs Market

The Anemia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases and anemia
    • Changing lifestyles and over-consumption of packaged and processed foods
    • Shifting demographics and growing number of women in reproductive stages
  • Market Restraints
    • Side effects associated with overconsumption of anemia drugs
  • Market Opportunities
    • Government approvals for the development of new and innovative anemia drugs
    • Research and development activities for the production of anemia drugs
  • Market Challenges
    • Recall of anemia drugs over safety concerns

Porter's Five Forces: A Strategic Tool for Navigating the Anemia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anemia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anemia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anemia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anemia Drugs Market

A detailed market share analysis in the Anemia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anemia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anemia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anemia Drugs Market

A strategic analysis of the Anemia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anemia Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc. by Allergan PLC, ADZO Lifesciences Pvt Ltd., Akebia Therapeutics, Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Aqunova Pharma Private Limited, Astraea Life Sciences Pvt Ltd, Bluebird Bio, Inc., Cadila Pharmaceuticals Ltd., Corona Remedies Pvt Ltd., Covis Pharma GmbH, Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Glenmark Pharmaceuticals Ltd., GSK PLC, Gujarat Terce Laboratories Ltd., Lupin Ltd., Pfizer Inc., Pharmacosmos A/S, Pieris Pharmaceuticals, Inc., Sanofi S.A., Solitaire Pharmacia Pvt. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, and Triton Healthcare Pvt Ltd..

Market Segmentation & Coverage

This research report categorizes the Anemia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Alglucerase Injection, Carbonyl Iron, Cyanocobalamin, Darbepoetin Alfa, Eculizumab, Epoetin Beta-methoxy Polyethylene Glycol, Ferrous FumarateIron, Iron Dextran, and Iron Supplements.
  • Based on Type, market is studied across Aplastic Anemia, Chronic Kidney Disease Anemia, Hemolytic Anemia, Iron Deficiency Anemia, Pernicious Anemia, Sickle Cell Anemia, and Vitamin Deficiency Anemia.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on End-Users, market is studied across Hospital and Self-Administered.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases and anemia
      • 5.1.1.2. Changing lifestyles and over-consumption of packaged and processed foods
      • 5.1.1.3. Shifting demographics and growing number of women in reproductive stages
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with overconsumption of anemia drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Government approvals for the development of new and innovative anemia drugs
      • 5.1.3.2. Research and development activities for the production of anemia drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Recall of anemia drugs over safety concerns
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anemia Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Alglucerase Injection
  • 6.3. Carbonyl Iron
  • 6.4. Cyanocobalamin
  • 6.5. Darbepoetin Alfa
  • 6.6. Eculizumab
  • 6.7. Epoetin Beta-methoxy Polyethylene Glycol
  • 6.8. Ferrous FumarateIron
  • 6.9. Iron Dextran
  • 6.10. Iron Supplements

7. Anemia Drugs Market, by Type

  • 7.1. Introduction
  • 7.2. Aplastic Anemia
  • 7.3. Chronic Kidney Disease Anemia
  • 7.4. Hemolytic Anemia
  • 7.5. Iron Deficiency Anemia
  • 7.6. Pernicious Anemia
  • 7.7. Sickle Cell Anemia
  • 7.8. Vitamin Deficiency Anemia

8. Anemia Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Anemia Drugs Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Self-Administered

10. Americas Anemia Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anemia Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anemia Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc. by Allergan PLC
  • 2. ADZO Lifesciences Pvt Ltd.
  • 3. Akebia Therapeutics, Inc.
  • 4. Alembic Pharmaceuticals Limited
  • 5. Alkem Laboratories Ltd.
  • 6. Aqunova Pharma Private Limited
  • 7. Astraea Life Sciences Pvt Ltd
  • 8. Bluebird Bio, Inc.
  • 9. Cadila Pharmaceuticals Ltd.
  • 10. Corona Remedies Pvt Ltd.
  • 11. Covis Pharma GmbH
  • 12. Dr. Reddy's Laboratories
  • 13. Emcure Pharmaceuticals
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. GSK PLC
  • 16. Gujarat Terce Laboratories Ltd.
  • 17. Lupin Ltd.
  • 18. Pfizer Inc.
  • 19. Pharmacosmos A/S
  • 20. Pieris Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. Solitaire Pharmacia Pvt. Ltd.
  • 23. Sun Pharmaceutical Industries Limited
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Triton Healthcare Pvt Ltd.

LIST OF FIGURES

  • FIGURE 1. ANEMIA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANEMIA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANEMIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANEMIA DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANEMIA DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANEMIA DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANEMIA DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANEMIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANEMIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANEMIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANEMIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANEMIA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ALGLUCERASE INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANEMIA DRUGS MARKET SIZE, BY CARBONYL IRON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANEMIA DRUGS MARKET SIZE, BY CYANOCOBALAMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANEMIA DRUGS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANEMIA DRUGS MARKET SIZE, BY EPOETIN BETA-METHOXY POLYETHYLENE GLYCOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANEMIA DRUGS MARKET SIZE, BY FERROUS FUMARATEIRON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANEMIA DRUGS MARKET SIZE, BY IRON DEXTRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANEMIA DRUGS MARKET SIZE, BY IRON SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANEMIA DRUGS MARKET SIZE, BY APLASTIC ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANEMIA DRUGS MARKET SIZE, BY CHRONIC KIDNEY DISEASE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANEMIA DRUGS MARKET SIZE, BY HEMOLYTIC ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANEMIA DRUGS MARKET SIZE, BY IRON DEFICIENCY ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANEMIA DRUGS MARKET SIZE, BY PERNICIOUS ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANEMIA DRUGS MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANEMIA DRUGS MARKET SIZE, BY VITAMIN DEFICIENCY ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANEMIA DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANEMIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANEMIA DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANEMIA DRUGS MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANEMIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANEMIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ANEMIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ANEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ANEMIA DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 199. ANEMIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 200. ANEMIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023